PTC Therapeutics Q3 net income $15.9M, Sephience launch revenue $19.6M

PTC THERAPEUTICS, INC.

2025-Q3 EPS reported $9.45 revenue$1,565,978,000

Total revenue $211.0M vs $196.8M YoY; net income $15.9M vs loss of $106.7M.
Sephience launch: $19.6M revenue (US $14.4M, ex-US $5.2M), 521 start forms from 141 prescribers, 341 patients on therapy.
DMD franchise revenue $85.9M (Translarna $50.7M, Emflaza $35.2M); Evrysdi royalties $70.8M.
Full-year 2025 revenue guidance narrowed to $750-$800M; GAAP R&D/SG&A $805-$835M.
Cash and marketable securities $1,687.8M as of Sep 30, 2025 (up from $1,139.7M at Dec 31, 2024).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.